No Data
No Data
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Sector Update: Health Care Stocks Edge Higher Premarket Monday
FDA Accepts Supernus Pharmaceuticals' Resubmission for Parkinson's Treatment Device, Decision Expected by February 2025
Express News | Supernus Pharmaceuticals Inc: Resubmission Is Now Considered Filed, With a User Fee Goal Date (Pdufa Date) of February 1, 2025.
Express News | Supernus Announces Spn-830 Apomorphine Infusion Device Nda Accepted for Review by FDA
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Not Quite Adding Up
Arrayfunction : Do you have any experience with Phase 4 / aftermarket trials for medical devices or durable medical equipment? That's something I would like to educate myself on but I honestly have a much harder time with devices. For one, my company doesn't really do those anymore. But mainly it's the extra categories (e.g. FDA authorized de novo and approval on the basis of similarities to an established device) that I struggle with.
I'd appreciate the help! But no worries if not
Jaguar8 OP Arrayfunction : No. I do not come from any clinical research companies and/or pharma which does Ph 4.
Arrayfunction Jaguar8 OP : Thanks!